Business Description
Gencurix Inc
ISIN : KR7229000005
Compare
Compare
Traded in other countries / regions
229000.Korea IPO Date
2015-10-27Description
Gencurix Inc develops diagnosis treatment kits. It offers products including GenesWell BCT, a breast cancer test; GenesWell ddEGFR Mutation Test; GenesWell CDx EGFR Mutation Test; and GenesWell ddEGFR mutation Test.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 1.13 | |||||
Debt-to-EBITDA | -1.05 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.24 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 20.7 | |||||
3-Year Book Growth Rate | -48.9 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.58 | |||||
9-Day RSI | 54.82 | |||||
14-Day RSI | 50.74 | |||||
6-1 Month Momentum % | -49.5 | |||||
12-1 Month Momentum % | -3.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.74 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.57 | |||||
Days Inventory | 225.67 | |||||
Days Sales Outstanding | 101.06 | |||||
Days Payable | 10.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.5 | |||||
Shareholder Yield % | -11.02 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 57.53 | |||||
Operating Margin % | -368.27 | |||||
Net Margin % | -564.61 | |||||
FCF Margin % | -434.36 | |||||
ROE % | -129.3 | |||||
ROA % | -48.29 | |||||
ROIC % | -27.01 | |||||
ROC (Joel Greenblatt) % | -117.04 | |||||
ROCE % | -96.13 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.48 | |||||
PB Ratio | 3.01 | |||||
Price-to-Tangible-Book | 3.18 | |||||
EV-to-EBIT | -3.02 | |||||
EV-to-EBITDA | -3.3 | |||||
EV-to-Revenue | 17.22 | |||||
EV-to-FCF | -3.91 | |||||
Earnings Yield (Greenblatt) % | -33.07 | |||||
FCF Yield % | -29.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gencurix Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 2,897.084 | ||
EPS (TTM) (â‚©) | -1163 | ||
Beta | 0.75 | ||
Volatility % | 74.33 | ||
14-Day RSI | 50.74 | ||
14-Day ATR (â‚©) | 131.976785 | ||
20-Day SMA (â‚©) | 2872.75 | ||
12-1 Month Momentum % | -3.06 | ||
52-Week Range (â‚©) | 2665 - 8910 | ||
Shares Outstanding (Mil) | 14.44 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Gencurix Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Gencurix Inc Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Gencurix Inc Frequently Asked Questions
What is Gencurix Inc(XKRX:229000)'s stock price today?
The current price of XKRX:229000 is â‚©2950.00. The 52 week high of XKRX:229000 is â‚©8910.00 and 52 week low is â‚©2665.00.
When is next earnings date of Gencurix Inc(XKRX:229000)?
The next earnings date of Gencurix Inc(XKRX:229000) is .
Does Gencurix Inc(XKRX:229000) pay dividends? If so, how much?
Gencurix Inc(XKRX:229000) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |